B‐Cell Differentiation of Human Hematopoietic Progenitors Is Efficiently Supported by Wharton Jelly‐Derived Mesenchymal Stem Cells
European Journal of Immunology · 2026-04 · 56 (4)
DOI: 10.1002/eji.70186 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 04.04.2026. Verfasst von Louison Collet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire HEMATIM UR4666, Université Picardie Jules Verne, Amiens, France. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Cell Differentiation, Wharton Jelly, Hematopoietic Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mesenchymal stem cells (MSC) represent the main stromal component of the bone marrow (BM) niche and are crucial to maintain hematopoietic tissue homeostasis. MSC exhibits extraordinary and multiple properties. In terms of expanding potential and differentiation capacity, Wharton jelly MSC (WJ‐MSC), derived from the umbilical cord, was described as being greater and more performing than MSC from BM or other sources. WJ‐MSC mimics the hematopoietic niche and supports hematopoietic stem cells (HSC) expansion ex vivo. This study aimed to evaluate the effects of human WJ‐MSC cocultured with HSC in a B‐cell differentiation protocol. Remarkably, results highlight WJ‐MSC use as a preferable feeder layer to efficiently support HSC commitment toward the B‐lineage. Over 11 days of HSC coculture with WJ‐MSC, B‐cell genes ( E2A , RAG1 , RAG2 , etc.) expression patterns and B‐cell markers (CD19, immunoglobulin chain, etc.) acquisition were evidenced. WJ‐MSc were also able to unlock the B‐lineage differentiation blockade of the acute lymphoblastic leukemia cell line Nalm16. This model might provide a new strategy to support ex vivo B‐cell differentiation using the powerful properties of WJ‐MSC. This study implements a new approach to improve understanding of B‐leukemogenesis and B‐cell acute lymphoblastic leukemia (B‐ALL) pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire HEMATIM UR4666, Université Picardie Jules Verne, Amiens, France.
- Service De Thérapie Cellulaire, Centre Hospitalier Universitaire, Amiens, France.
- Service D'immunologie, Centre Hospitalier Universitaire, Amiens, France.
- Service D'hématologie Biologique, Centre Hospitalier Universitaire, Amiens, France.
- Service D'hématologie Clinique, Centre Hospitalier Universitaire, Amiens, France.
Zitieren
APA
Collet, L., Ouled-Haddou, H., Ghamlouch, H., Darwiche, W., Gomila, C., Gubler, B., Garcon, L., Lebon, D., & Marolleau, J. P. (2026). B‐Cell Differentiation of Human Hematopoietic Progenitors Is Efficiently Supported by Wharton Jelly‐Derived Mesenchymal Stem Cells. European Journal of Immunology, 56(4). https://doi.org/10.1002/eji.70186
Vancouver
Collet L, Ouled-Haddou H, Ghamlouch H, Darwiche W, Gomila C, Gubler B, et al. B‐Cell Differentiation of Human Hematopoietic Progenitors Is Efficiently Supported by Wharton Jelly‐Derived Mesenchymal Stem Cells. European Journal of Immunology. 2026;56(4). doi:10.1002/eji.70186
BibTeX
@article{Collet2026,
author = {Collet, Louison and Ouled-Haddou, Hakim and Ghamlouch, Hussein and Darwiche, Walaa and Gomila, Cathy and Gubler, Brigitte and Garcon, Loïc and Lebon, Delphine and Marolleau, Jean-Pierre},
title = {B‐Cell Differentiation of Human Hematopoietic Progenitors Is Efficiently Supported by Wharton Jelly‐Derived Mesenchymal Stem Cells},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {4},
doi = {10.1002/eji.70186}
}
EUVIMED